Krug et al. screened exosomal RNA and cfDNA in parallel from a cohort of 84 EGFR positive NSCLC patients (stage IIIB, IV) enrolled in TIGER-X (NCT01526928), a phase 1–2 trial to receive rociletinib [84]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.